The primary aim of this study is to investigate the methylation status of DDIT3 promoter in CML patients and determine the association of DDIT3 methylation with the patients' clinical features. This evidence concerns the gene DDIT3 and chronic myelogenous leukemia, BCR-ABL1 positive.